絞り込み

16633

広告

宇宙ビジネス シニア人材をベンチャー企業に!

宇宙ビジネス分野のベンチャー企業に、JAXA=宇宙航空研究開発機構などのシニア人材を引き合わせる取り組みがこの秋から始まります。経済産業省が主導し、日本の宇宙産...

  1. タイ:プラごみ誤飲 ジュゴンの赤ちゃん死...
  2. 優生社会を問う:新型出生前診断 利益大き...
  3. 安定狭心症患者に対する鍼治療のRCT (...
  4. 咳嗽診療、どこから「本気」を出す? (日...

ニュース一覧

Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

著者 Akhtar OS , Attwood K , Lund I , Hare R , Hernandez-Ilizaliturri FJ , Torka P
Leuk Lymphoma.2019 Jan 02 ; ():1-6.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

Miscellaneous

Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, judicious dose reductions could result in improved tolerance. Our objective was to study the impact of dose reductions on outcomes in CLL patients treated with ibrutinib in a real-world setting. We identified 70 CLL patients treated with ibrutinib at Roswell Park Comprehensive Cancer Center between January 2014 and June 2017. Twenty-three (31.3%) patients required dose reductions. There was no statistically significant difference in overall response rate (ORR), clinical benefit rate (CBR), median progression-free survival, and overall survival (OS) between the dose-reduced and standard-dose groups (SDGs). These results extended to all patients, irrespective of whether the modification was made within three months of treatment initiation, or later.
PMID: 30601100 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード